MARKET

XTLB

XTLB

Xtl Biopharmaceu
NASDAQ
0.9536
-0.0036
-0.38%
Opening 09:30 02/10 EST
OPEN
--
PREV CLOSE
0.9536
HIGH
--
LOW
--
VOLUME
1
TURNOVER
608
52 WEEK HIGH
2.570
52 WEEK LOW
0.5301
MARKET CAP
9.02M
P/E (TTM)
-1.3067
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XTLB last week (0202-0206)?
Weekly Report · 1d ago
Weekly Report: what happened at XTLB last week (0126-0130)?
Weekly Report · 02/02 10:14
XTL Biopharmaceuticals provides update on recent developments
TipRanks · 01/29 21:40
XTL Biopharmaceuticals Moves To Acquire 85% Of NeuroNOS And Has Already Scheduled A Shareholders Meeting For February 17, 2026 To Approve A Private Placement Of Up To $2M
Benzinga · 01/29 21:29
XTL Biopharmaceuticals Moves to Acquire 85% Stake in NeuroNOS Ltd
Reuters · 01/29 21:07
XTL Biopharmaceuticals Schedules Shareholder Vote on $2 Million Private Placement Proposal
Reuters · 01/29 21:06
XTL Biopharmaceuticals Advances NeuroNOS Acquisition and Plans $2 Million Private Placement to Address Nasdaq Equity Deficiency
TipRanks · 01/28 14:17
Weekly Report: what happened at XTLB last week (0119-0123)?
Weekly Report · 01/26 10:13
More
About XTLB
X T L Biopharmaceuticals Ltd (Xenograft Technologies Ltd) is an Israel-based biopharmaceutical company engaged in acquisition and development of pharmaceutical drugs for treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

Webull offers X T L Biopharmaceuticals Ltd (ADR) stock information, including NASDAQ: XTLB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XTLB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XTLB stock methods without spending real money on the virtual paper trading platform.